Ülke: Avustralya
Dil: İngilizce
Kaynak: Department of Health (Therapeutic Goods Administration)
Nitisinone
A Menarini Australia Pty Ltd
Medicine Registered
_Consumer Medicine Information _ _ _ _ORFADIN® _ ORFADIN ® 2 MG, 5 MG, 10 MG NITISINONE CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Orfadin hard capsules. It does not contain all of the available information. Reading this leaflet does not take the place of talking to your doctor. All medicines have risks and benefits. Your doctor has weighed the risks of your taking Orfadin against the benefits they expect it will have for you. If you have any concerns about taking Orfadin, ask your doctor. Keep this leaflet with the medicine. You may want to read it again. WHAT OFRADIN IS USED FOR Orfadin contains a medicine called nitisinone which is used for the treatment of a disease called hereditary tyrosinaemia type 1. In this disease the body is unable to completely break down the amino acid tyrosine. Harmful substances will be formed and accumulated in the body. Orfadin blocks the breakdown of tyrosine and by doing so the harmful substances are not formed. HOWEVER, TYROSINE WILL REMAIN IN THE BODY AND THEREFORE A SPECIAL DIET (WITH LOW TYROSINE AND PHENYLALANINE CONTENT) MUST BE FOLLOWED WHEN TAKING ORFADIN. Nitisinone belongs to a group of medicines called ‘other alimentary and metabolism products’. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY ORFADIN HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another use. Orfadin is not addictive. Orfadin is only available on a doctor's prescription. BEFORE YOU TAKE ORFADIN _YOU SHOULD DISCUSS WITH YOUR DOCTOR IF _ _YOU_: • have a history of hypersensitivity (an allergy) to the active substance or any of the other ingredients listed at the end of this Belgenin tamamını okuyun
ORFADIN (NITISINONE) NAME OF THE MEDICINE Nitisinone, 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane- 1,3 -dione Molecular Formula: C14H10F3NO5 Molecular Weight: 329.23 Chemical Structure: CAS Registry Number: 104206-65-7. DESCRIPTION Orfadin capsules are white, opaque, hard gelatine capsules, imprinted with “NTBC” and the strength “2 mg”, “5 mg” or “10 mg” in black. The active substance is a weak acid and it is highly soluble in the pH range 4.5 - 7.2 according to the Biopharmaceutics classification system. Partition coefficient for nitisinone in octanol/water at pH 6.5 is 0.432. Each capsule contains 2 mg, 5 mg or 10 mg nitisinone, plus pregelatinised starch (maize). The capsule shell is gelatine and titanium dioxide. The imprint is either Opacode monogramming ink S-1-27794 Black (ARTG ID: 12104) or TekPrint SW-9008 Black Ink (ARTG ID: 2328). PHARMACOLOGY Pharmacotherapeutic group: Other alimentary and metabolism products. ATC code: A16A X04. The biochemical defect in hereditary tyrosinaemia type 1 (HT-1) is a deficiency of fumarylacetoacetate hydrolase, which is the final enzyme of the tyrosine catabolic pathway. Nitisinone is a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, an enzyme which precedes fumarylacetoacetate hydrolase in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the toxic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate. Succinylacetone inhibits the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate. 1 ORFi-01 PHARMACOKINETICS Formal absorption, distribution, meta Belgenin tamamını okuyun